4.7 Article

Development of PEGylated Cysteine-Modified Lysine Dendrimers with Multiple Reduced Thiols To Prevent Hepatic Ischemia/Reperfusion Injury

Journal

MOLECULAR PHARMACEUTICS
Volume 13, Issue 8, Pages 2867-2873

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.6b00557

Keywords

drug delivery; dendrimer; PEGylation; cysteine; thiol; reactive oxygen species; hepatic ischemia/reperfusion injury

Ask authors/readers for more resources

To inhibit hepatic ischemia/reperfusion injury, we developed polyethylene glycol (PEG) conjugated (PEGylated) cysteine-modified lysine dendrimers with multiple reduced thiols, which function as scavengers of reactive oxygen species (ROS). Second, third, and fourth generation (K2, K3, and K4) highly branched amino acid spherical lysine dendrimers were synthesized, and cysteine (C) was conjugated to the outer layer of these lysine dendrimers to obtain K2C, K3C, and K4C dendrimers. Subsequently, PEG was reacted with the C residues of the dendrimers to obtain PEGylated dendrimers with multiple reduced thiols (K2C PEG, K3C-PEG, and K4C-PEG). Radiolabeled K4C-PEG (In-111-k4C-PEG) exhibited prolonged retention in the plasma, whereas In-111-K2C-PEG and In-111-K3C-PEG rapidly disappeared from the plasma. K4C-PEG significantly prevented the elevation of plasma alanine, aminotransferase (ALT) activity, an index of hepatocyte injury, in. a mouse model of hepatic ischemia/reperfusion injury. In contrast, K2C PEG, K3C PEG, L-cysteine, and glutathione, the latter two of which are:classical reduced thiols, hardly affected the plasma ALT activity. These findings indicate that K4C PEG with prolonged circulation time is a promising compound to inhibit hepatic ischemia/reperfusion injury.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available